Guide to the Ongoing Xarelto LitigationLegal Herald provides you today with a clear and helpful guide to the ongoing Xarelto litigation, explaining the MDL and the allegations against the drug. The Xarelto multidistrict litigation has been proceeding for almost one year now and in that time, many events have happened. Today we are providing you with a helpful, up to date guide to the litigation and MDL process for federally filed Xarelto cases. For more detailed information about the Xarelto lawsuits, visit this page.
Xarelto’s Time on the U.S. MarketXarelto, the brand name for the generic drug rivaroxaban, was first approved by the Food and Drug Administration (FDA) in 2011 to help prevent blood clots and deep vein thrombosis in patients who have recently undergone hip or knee replacement surgery, to treat patients who suffer from atrial fibrillation, and for the general purpose of reducing blood clots. Xarelto is manufactured by pharmaceutical conglomerates Bayer AG and Johnson&Johnson's pharmaceutical unit, Janssen Pharmaceuticals.
Lawsuits Allege Xarelto Has Dangerous Side EffectsMany of the current Xarelto lawsuits allege that the drug has dangerous side effects, mainly that the drug can cause serious internal bleeding that can become uncontrollable and leave the patient with severe injuries. They allege that the drug is particularly dangerous because there is no reversal antidote to reverse its anticoagulant effects. This is very different than traditional blood thinners, like Warfarin, where in the event of an internal bleed a doctor can administer Vitamin K and the patient’s blood will begin to clot again. If a patient taking Xarelto suffers from an internal bleeding injury, there is no way to stop the bleeding.
Xarelto Lawsuits Filed By VictimsThe first Xarelto lawsuit was filed in January 2014. The lawsuit alleged that Xarelto was the cause of the patient's death because of an uncontrollable internal bleeding incident brought on by the drug. Since then, most of the lawsuits filed allege that Xarelto caused the individual uncontrollable internal bleeding which resulted in death or other serious injury. Due to the large and growing number of lawsuits filed, they were consolidated into a Federal Multidistrict Litigation panel in December 2014. The MDL is based in New Orleans, Louisiana and is presided over by Judge Eldon Fallon. In addition to the Federal MDL, a number of lawsuits filed in Pennsylvania have been consolidated into a mass tort group in Philadelphia. The Xarelto MDL is still in the pretrial stages and the bellwether trials will be taking place in early 2017.
FDA Warnings Against XareltoThe FDA issued a warning in August 2013 that made the public aware that stopping a Xarelto regimen prematurely leads to a higher risk of blood clots and despite this warning, in 2013 Xarelto manufacturers profited with $1.4 billion of Xarelto sales. Xarelto currently has two black box warnings attached to it by the FDA. The black box warning is the strictest warning the FDA can attach to a drug. It means that there is a reasonable risk of harm associated with taking the drug.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.